Mineralcorticoid Antagonists in Heart Failure

Heart Failure Clinics

Volumn 10, Issue 4, 2014, Pages 559-564

  D'Elia, Emilia ^a,b   Krum, Henry ^c  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Aldosterone; Heart failure; Mineralcorticoid receptor agonists

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG;

CARDIAC PATIENT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HOSPITAL READMISSION; HUMAN; KIDNEY FUNCTION; NEW YORK HEART ASSOCIATION CLASS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASOCONSTRICTION; CLINICAL TRIAL (TOPIC); PHYSIOLOGY;

ALDOSTERONE; CANRENONE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

EID: 84908019938     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.07.003     Document Type: Review

References (23)

1. Francis G.S., Goldsmith S.R., Levine B.T., et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984, 101:370-377.
2. Gavazzi A. Fisiopatologia. Lo scompenso cardiaco 2002, 25-50. Scripta Manent snc Ed, Milano (Italy). A. Gavazzi (Ed.).
3. Dzau V.J., Gibbson G.H. Autocrine-paracrine mechanisms of vascular myocytes in hypertension. Am J Cardiol 1987, 60:991.
4. Konstam M.A., Rousseau M.F., Kronenberg M.W., et al. Effects of angiotensin converting enzyme inhibitor, enalapril, on long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992, 86:431-438.
5. Swedberg K., Eneroth P., Krjekshus J., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990, 82:1730-1736.
6. Francis G.S., Cohn J.N., Johnson G., et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(Suppl VI):VI-40-VI-48.
7. Benedict C.R., Weiner D.H., Johnstone D.E., et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. JAm Coll Cardiol 1993, 22(Suppl A):146A-153A.
8. Staessen J., Lijnen P., Fagard R., et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. JEndocrinol 1981, 91:457-465.
9. Borghi C., Boschi S., Ambrosioni E., et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE-inhibitors. JClin Pharmacol 1993, 33:40-45.
10. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. NEngl J Med 1987, 316:1429-1435.
11. Greco C., Castelli G., Crea F., et al. Nuove evidenze sull'impiego degli antialdosteronici nella disfunzione ventricolare sinistra: spironolattone ed eplerenone. Dal postinfarto allo scompenso cardiaco. GItal Cardiol 2012, 13:809-816.
12. Albaghdadi M., Gheorghiade M., Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 2011, 32:2626-2633.
13. Macdonald J.E., Kennedy N., Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90:765-770.
14. Pitt B., Zannad F., Remme W., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEngl J Med 1999, 341:709-717.
15. Boccanelli A., Mureddu G.F., Cacciatore G., et al. onbehalf of AREA IN-CHF Investigators. Anti-remodeling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009, 11:68-76.
16. Pitt B., Remme W., Zannad F., for the Eplerenone Post-acute Myocardial Infarction Efficacy and survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348:1309-1321.
17. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364:11-21.
18. Krum H., Shi H., Pitt B., et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 2013, 6(4):711-718.
19. Rogers J.K., McMurray J.J., Pocock S.J., et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation 2012, 126:2317-2323.
20. Pitt B., Pfeffer M.A., Assmann S.F., et al. TOPCAT investigators. Spironolactone for heart failure with preserved ejection fraction. NEngl J Med 2014, 370:1383-1392.
21. Pitt B., Kober L., Ponikowski P., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013, 34:2453-2463.
22. Calhoun D.A., White W.B., Krum H., et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011, 124:1945-1955.
23. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012, 33:1787-1847.